Drugs / RLD2002
Trials 0
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05723549 Comparator | Feb → Mar 2023 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05362110 Comparator | May 2022 → Jun 2023 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RLD2002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05362110 ↗ |